MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap Down – Here’s Why

MoonLake Immunotherapeutics (NASDAQ:MLTX)’s stock price gapped down prior to trading on Thursday . The stock had previously closed at $17.41, but opened at $16.48. MoonLake Immunotherapeutics shares last traded at $16.4330, with a volume of 417,865 shares traded.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on MLTX shares. Citigroup downgraded MoonLake Immunotherapeutics from a “neutral” rating to a “sell” rating in a research note on Wednesday, October 29th. Jefferies Financial Group cut shares of MoonLake Immunotherapeutics from a “buy” rating to a “hold” rating and set a $8.00 price objective for the company. in a research note on Monday, September 29th. The Goldman Sachs Group cut shares of MoonLake Immunotherapeutics from a “neutral” rating to a “sell” rating and upped their target price for the company from $8.00 to $10.00 in a research report on Wednesday. Wolfe Research downgraded MoonLake Immunotherapeutics from an “outperform” rating to an “underperform” rating in a research report on Tuesday, September 30th. Finally, Wedbush dropped their target price on MoonLake Immunotherapeutics from $80.00 to $18.00 and set an “outperform” rating for the company in a report on Tuesday, September 30th. Seven equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and four have given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $25.77.

MoonLake Immunotherapeutics Price Performance

The stock’s 50 day moving average price is $13.62 and its 200-day moving average price is $30.84. The company has a quick ratio of 8.50, a current ratio of 8.50 and a debt-to-equity ratio of 0.25. The stock has a market capitalization of $1.07 billion, a PE ratio of -5.01 and a beta of 1.21.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last issued its earnings results on Wednesday, November 5th. The company reported ($1.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.21). During the same period last year, the company posted ($0.56) EPS. As a group, equities analysts forecast that MoonLake Immunotherapeutics will post -1.79 EPS for the current year.

Insider Buying and Selling at MoonLake Immunotherapeutics

In other MoonLake Immunotherapeutics news, insider Kristian Reich sold 72,908 shares of the company’s stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $14.43, for a total transaction of $1,052,062.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Da Silva Jorge Santos sold 70,000 shares of the stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $14.49, for a total value of $1,014,300.00. Following the sale, the chief executive officer directly owned 2,878,577 shares in the company, valued at $41,710,580.73. This trade represents a 2.37% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 402,908 shares of company stock valued at $5,987,162 over the last quarter. Company insiders own 12.02% of the company’s stock.

Hedge Funds Weigh In On MoonLake Immunotherapeutics

Large investors have recently added to or reduced their stakes in the company. Schonfeld Strategic Advisors LLC purchased a new stake in MoonLake Immunotherapeutics during the third quarter valued at approximately $6,922,000. Two Sigma Investments LP purchased a new stake in shares of MoonLake Immunotherapeutics during the 3rd quarter valued at $3,257,000. Vestal Point Capital LP boosted its position in shares of MoonLake Immunotherapeutics by 175.0% in the 2nd quarter. Vestal Point Capital LP now owns 550,000 shares of the company’s stock worth $25,960,000 after purchasing an additional 350,000 shares in the last quarter. Balyasny Asset Management L.P. grew its stake in MoonLake Immunotherapeutics by 436.8% during the 2nd quarter. Balyasny Asset Management L.P. now owns 423,170 shares of the company’s stock worth $19,974,000 after buying an additional 344,335 shares during the last quarter. Finally, Millennium Management LLC increased its position in MoonLake Immunotherapeutics by 3,343.2% during the 1st quarter. Millennium Management LLC now owns 344,320 shares of the company’s stock valued at $13,453,000 after buying an additional 334,320 shares in the last quarter. 93.85% of the stock is currently owned by institutional investors.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunomodulatory therapies for autoimmune and inflammatory diseases. The company leverages a proprietary platform designed to selectively modulate key immune cell populations, aiming to restore immune balance and reduce tissue damage with targeted biologic candidates.

Its lead asset, MLTX101, is a recombinant immune cell modulator in clinical development for myositis, including inclusion body myositis and dermatomyositis.